Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago.

An initiative to expand utilization of remote monitoring to marginalized populations — developed and deployed through the ...

Researchers at Penn Medicine conducted a pilot randomized controlled trial to test the hypothesis that an e-triage ...

The causes of obesity are complex and influenced by many factors. While research has highlighted connections between sleep, eating patterns and weight gain, scientists remain uncertain of the role of ...

A new article published this week in The Lancet medical journal found that more than half of the world's population lacks ...

From cataracts to macular degeneration, discover the 5 leading causes of permanent vision loss and expert-recommended strategies to protect your eyesight.

The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

APL was once a highly fatal disease, with up to 30% of patients dying early from complications. Traditional treatments often ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

The National Institutes of Health's new funding requirements will remove administrative bloat and ideological agendas from ...